NCT07393867RecruitingPhase 2
Androgen-responsive POSLUMA-guided Intra-prostatic Boost
Androgen-responsive POSLUMA-guided Intra-prostatic Boost (ARPEGGIO)
Source: ClinicalTrials.gov · Last updated 29 May 2026
Brief summary (registry, in English)
This research study is for men with intermediate- or high-risk prostate cancer who are planning to receive hormone therapy and radiation treatment. The purpose of the study is to see whether a special type of diagnostic imaging done during hormone therapy can help doctors more accurately target remaining cancer with radiation, while avoiding areas that may no longer need extra treatment. All participants will receive standard hormone therapy and radiation therapy, along with three imaging scans, over a six-month period. The information gained from this study may help make prostate cancer radiation treatment more precise and reduce side effects for future patients.
- Status (registry)
- Recruiting
- Phase (registry)
- Phase 2
- Study type
- Interventional
- Enrollment
- 23 (estimated)
- First submitted
- 27 Jan 2026
- Start date
- 29 Apr 2026
- Primary completion date
- 15 Dec 2026
- Lead sponsor
- Martin T. King, MD, PhD
- Diseases
- Prostate cancer
- NCT number
- NCT07393867
What you commit to
- Study type: Interventional · Phase 2
- Planned participants: 23
- From 29 Apr 2026 to the primary completion date, 15 Dec 2026
- 4 sites in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Prior imaging (CT, bone scan, MRI, PSMA-PET/CT) showing nodal or distant disease.
- Intention to receive treatment intensification with secondary androgen receptor signaling inhibitors or chemotherapy.
- Prior ADT.
- Prior pelvic RT.
- Prior prostate surgery, including TURP.
- Prior urethral stricture.
- Hip implants that cause artifacts over the prostate gland.
Other illness
- Clinical T4 disease.
- Active Crohn's disease or scleroderma.
Other
- International prostate symptom score \> 20.
- Prostate volume \> 80 cc on MRI.
- Inability to discontinue anti-coagulation for fiducial marker placement.
Who the study is looking for
- 18 years of age and older.
- Eastern Oncology Group Status 0 to 1.
- Histologic diagnosis of prostate cancer.
- Prior screening MRI with at least one PI-RADS4 or PI-RADS 5 lesion, obtained within 180 days of screening.
- NCCN intermediate-risk or high-risk prostate cancer (Appendix B). All patients will be staged by MRI.
- Prior PSMA PET scan with at least one focal avid lesion greater than background prostate that is concordant with a lesion on MRI, obtained within 180 days of screening.
- Intention for SBRT (36.25 Gy/5 fraction) with focal boost (up to 50 Gy) to one MRI/PET-concordant lesion34.
Age in the registry: 18 years to - · Sex: Male · Does not accept healthy volunteers
Sites (4)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Dana-Farber Cancer Institute Coordinator of this site? Confirm its status | Boston | United States | Not yet recruiting |
| Brigham and Women's Hospital Coordinator of this site? Confirm its status | Boston | United States | Not yet recruiting |
| Dana-Farber/Brigham and Women's Cancer Center at Milford Regional Medical Center Coordinator of this site? Confirm its status | Milford | United States | Recruiting |
| Dana-Farber/Brigham and Women's Cancer Center in clinical affiliation with South Shore Hospital Coordinator of this site? Confirm its status | Weymouth | United States | Recruiting |
This page is information, not medical advice. Discuss any trial with your doctor.